Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has expanded its pharmaceutical contract manufacturing agreement with UCB, increasing the contract value by KRW 381.9B from KRW 45.1B to KRW 427.0B, while disclosing the counterparty and contract end date (2030-12-31).
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Change in contract value upon customer request
- Contract Title: Contract Manufacturing Agreement for Pharmaceutical Products
- Counterparty: UCB (Previously withheld due to business confidentiality, now disclosed)
- Pre-correction Contract Amount: KRW 45,107,116,600 (15.31% of Recent Annual Revenue) / USD 41,654,000
- Post-correction Contract Amount: KRW 427,002,630,600 (144.93% of Recent Annual Revenue) / USD 394,314,000
- Increased Value: KRW 381,895,514,000 (USD 352,660,000 increase)
- Recent Annual Revenue: KRW 294,622,020,774
- Initial Contract Date & Initial Disclosure Date: December 21, 2017 (Applied Exchange Rate: USD/KRW 1,082.90)
- Post-correction Contract Period: December 21, 2017 ~ December 31, 2030 (End date disclosed)
- Other Remarks: Definitive contract execution for the LOI disclosed on May 4, 2017; contract end date is subject to change based on mutual agreement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Revenue Recognition and Term Adjustments Following Major Value Expansion
This correction disclosure reports a substantial expansion in the contract manufacturing agreement originally executed in 2017, increasing the value from KRW 45.1B to KRW 427.0B upon customer request while disclosing the counterparty (UCB) and contract period. Because long-term supply agreements remain subject to potential amendments in terms depending on mutual agreement, tracking how this expanded value is recognized as actual revenue over time is essential. Verifying this progression helps investors understand the concrete financial impact of the updated contract terms on financial statements over the long term. Relevant updates can be verified through subsequent Quarterly, Half-Yearly, and Annual Reports, as well as notes to financial statements.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
